| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
|
Lancet Oncol
|
2012
|
6.20
|
|
2
|
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.
|
Nature
|
2011
|
4.63
|
|
3
|
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
|
Cancer Res
|
2004
|
2.35
|
|
4
|
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
|
J Clin Oncol
|
2007
|
2.11
|
|
5
|
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
|
Neurology
|
2013
|
1.98
|
|
6
|
Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R.
|
Stem Cells
|
2009
|
1.72
|
|
7
|
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
|
Acta Neuropathol
|
2014
|
1.66
|
|
8
|
MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
|
Cancer Res
|
2003
|
1.60
|
|
9
|
New (alternative) temozolomide regimens for the treatment of glioma.
|
Neuro Oncol
|
2008
|
1.58
|
|
10
|
ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
|
Acta Neuropathol
|
2013
|
1.58
|
|
11
|
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
|
Acta Neuropathol
|
2013
|
1.49
|
|
12
|
Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.
|
Acta Neuropathol
|
2014
|
1.42
|
|
13
|
Angiotensin II sustains brain inflammation in mice via TGF-beta.
|
J Clin Invest
|
2010
|
1.39
|
|
14
|
Pathway inhibition: emerging molecular targets for treating glioblastoma.
|
Neuro Oncol
|
2011
|
1.38
|
|
15
|
The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
|
PLoS One
|
2011
|
1.32
|
|
16
|
Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle.
|
PLoS Biol
|
2007
|
1.23
|
|
17
|
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.
|
Proc Natl Acad Sci U S A
|
2013
|
1.20
|
|
18
|
Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.
|
Histopathology
|
2011
|
1.16
|
|
19
|
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
|
Acta Neuropathol
|
2015
|
1.13
|
|
20
|
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR.
|
Oncotarget
|
2014
|
1.11
|
|
21
|
Bevacizumab does not increase the risk of remote relapse in malignant glioma.
|
Ann Neurol
|
2011
|
1.10
|
|
22
|
A novel tool to analyze MRI recurrence patterns in glioblastoma.
|
Neuro Oncol
|
2008
|
1.04
|
|
23
|
Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.
|
Clin Cancer Res
|
2011
|
1.03
|
|
24
|
Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression.
|
Acta Neuropathol
|
2011
|
1.00
|
|
25
|
Multiple sclerosis: trapped in deadly glue.
|
Nat Med
|
2005
|
0.97
|
|
26
|
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
|
Acta Neuropathol
|
2015
|
0.97
|
|
27
|
Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1).
|
Stem Cells Dev
|
2010
|
0.97
|
|
28
|
Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases.
|
Pathology
|
2005
|
0.97
|
|
29
|
Proximity ligation assay evaluates IDH1R132H presentation in gliomas.
|
J Clin Invest
|
2015
|
0.97
|
|
30
|
Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.
|
Neuro Oncol
|
2013
|
0.95
|
|
31
|
A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease.
|
J Immunol
|
2005
|
0.94
|
|
32
|
The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress.
|
Cancer Res
|
2013
|
0.92
|
|
33
|
Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.
|
Neuro Oncol
|
2013
|
0.90
|
|
34
|
Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma.
|
J Neuroimmunol
|
2013
|
0.89
|
|
35
|
Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis.
|
Proc Natl Acad Sci U S A
|
2013
|
0.88
|
|
36
|
Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.
|
PLoS One
|
2012
|
0.87
|
|
37
|
Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma.
|
J Neurooncol
|
2014
|
0.84
|
|
38
|
Good maths is needed to understand CMV data in glioblastoma.
|
Int J Cancer
|
2013
|
0.84
|
|
39
|
Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma.
|
BMC Cancer
|
2011
|
0.83
|
|
40
|
Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10.
|
Biochem Pharmacol
|
2011
|
0.83
|
|
41
|
Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway.
|
Glia
|
2014
|
0.82
|
|
42
|
Geriatric neuro-oncology: from mythology to biology.
|
Curr Opin Neurol
|
2011
|
0.81
|
|
43
|
CMV infection and glioma, a highly controversial concept struggling in the clinical arena.
|
Neuro Oncol
|
2014
|
0.80
|
|
44
|
Knowledge of HIV and factors associated with attitudes towards HIV among final-year medical students at Hanoi medical university in Vietnam.
|
BMC Public Health
|
2014
|
0.79
|
|
45
|
Challenging cytomegalovirus data in glioblastoma.
|
Neuro Oncol
|
2013
|
0.79
|
|
46
|
Defective p53 antiangiogenic signaling in glioblastoma.
|
Neuro Oncol
|
2010
|
0.79
|
|
47
|
Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands.
|
Mod Pathol
|
2009
|
0.78
|
|
48
|
BRAF p.Val600Glu (V600E) mutation detection in thyroid fine needle aspiration cell block samples: a feasibility study.
|
Pathology
|
2015
|
0.78
|
|
49
|
Functional MHC class II is upregulated in neurofibromin-deficient Schwann cells.
|
J Invest Dermatol
|
2013
|
0.78
|
|
50
|
Treatment of anaplastic glioma.
|
Cancer Treat Res
|
2015
|
0.77
|
|
51
|
Extravascular migratory metastasis in gynaecological carcinosarcoma.
|
Histopathology
|
2014
|
0.76
|
|
52
|
The aryl hydrocarbon receptor as a promoter of malignant glioma.
|
Cell Cycle
|
2012
|
0.76
|
|
53
|
EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough?
|
Neuro Oncol
|
2017
|
0.75
|
|
54
|
The promises of immunotherapy in gliomas.
|
Curr Opin Neurol
|
2017
|
0.75
|